1. Home
  2. LCTX vs SSP Comparison

LCTX vs SSP Comparison

Compare LCTX & SSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LCTX
  • SSP
  • Stock Information
  • Founded
  • LCTX 1990
  • SSP 1878
  • Country
  • LCTX United States
  • SSP United States
  • Employees
  • LCTX N/A
  • SSP N/A
  • Industry
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • SSP Broadcasting
  • Sector
  • LCTX Health Care
  • SSP Industrials
  • Exchange
  • LCTX Nasdaq
  • SSP Nasdaq
  • Market Cap
  • LCTX 107.3M
  • SSP 252.6M
  • IPO Year
  • LCTX N/A
  • SSP 1988
  • Fundamental
  • Price
  • LCTX $1.02
  • SSP $3.17
  • Analyst Decision
  • LCTX Strong Buy
  • SSP Strong Buy
  • Analyst Count
  • LCTX 5
  • SSP 1
  • Target Price
  • LCTX $4.20
  • SSP $8.00
  • AVG Volume (30 Days)
  • LCTX 4.6M
  • SSP 906.8K
  • Earning Date
  • LCTX 08-07-2025
  • SSP 08-07-2025
  • Dividend Yield
  • LCTX N/A
  • SSP N/A
  • EPS Growth
  • LCTX N/A
  • SSP N/A
  • EPS
  • LCTX N/A
  • SSP 0.93
  • Revenue
  • LCTX $9,557,000.00
  • SSP $2,472,701,000.00
  • Revenue This Year
  • LCTX N/A
  • SSP N/A
  • Revenue Next Year
  • LCTX $232.66
  • SSP $9.51
  • P/E Ratio
  • LCTX N/A
  • SSP $3.57
  • Revenue Growth
  • LCTX 19.42
  • SSP 6.28
  • 52 Week Low
  • LCTX $0.37
  • SSP $1.36
  • 52 Week High
  • LCTX $1.15
  • SSP $4.06
  • Technical
  • Relative Strength Index (RSI)
  • LCTX 66.66
  • SSP 67.71
  • Support Level
  • LCTX $0.85
  • SSP $2.70
  • Resistance Level
  • LCTX $1.15
  • SSP $3.17
  • Average True Range (ATR)
  • LCTX 0.12
  • SSP 0.22
  • MACD
  • LCTX -0.00
  • SSP 0.03
  • Stochastic Oscillator
  • LCTX 69.57
  • SSP 94.74

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

About SSP E.W. Scripps Company (The)

The E W Scripps Co is a media enterprise with interests in local and national media brands. It owns and operates a collection of daily and community newspapers in medium-sized cities in the southern and western portions of the United States. The company's operating segment includes Local Media, Scripps Networks, and Other. It generates maximum revenue from the Local Media segment. The Local Media segment includes local broadcast stations and their related digital operations.

Share on Social Networks: